Elevation in Inflammatory Serum Biomarkers Predicts Response to Trastuzumab-Containing Therapy

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Alkhateeb, Ahmed A ^a   Leitzel, Kim ^a   Ali, Suhail M ^a,b   Campbell Baird, Cynthia ^a   Evans, Matthew ^a   Fuchs, Eva Maria ^c   Köstler, Wolfgang J ^c   Lipton, Allan ^a   Connor, James ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; FERRITIN; TRASTUZUMAB;

ADULT; ARTICLE; C REACTIVE PROTEIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; FERRITIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; INFLAMMATORY BREAST CANCER; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SURVIVAL TIME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; C-REACTIVE PROTEIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITINS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MIDDLE AGED; RECEPTOR, ERBB-2; SURVIVAL RATE;

EID: 84871540704     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051379     Document Type: Article

References (37)

1. Coussens LM, Werb Z, (2002) Inflammation and cancer. Nature 420: 860-867.
2. Joyce JA, Pollard JW, (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252.
3. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, et al. (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28: 1467-1472.
4. Cotterchio M, Kreiger N, Sloan M, Steingart A, (2001) Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10: 1213-1217.
5. Johnson TW, Anderson KE, Lazovich D, Folsom AR, (2002) Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 11: 1586-1591.
6. Jones BM, Worwood M, Jacobs A, (1980) Serum ferritin in patients with cancer: determination with antibodies to HeLa cell and spleen ferritin. Clin Chim Acta 106: 203-214.
7. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, et al. (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27: 3437-3444.
8. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE, (2011) Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res 13: R55.
9. Robertson JF, Pearson D, Price MR, Selby C, Pearson J, et al. (1991) Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol Immunother 33: 403-410.
10. Jacobs A, Jones B, Ricketts C, Bulbrook RD, Wang DY, (1976) Serum ferritin concentration in early breast cancer. Br J Cancer 34: 286-290.
11. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, et al. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54-67.
12. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, et al. (2011) Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 25: 2465-2479.
13. Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, et al. (2012) Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21: 488-503.
14. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, et al. (2010) Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 115: 1461-1471.
15. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
16. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
17. Kostler WJ, Schwab B, Singer CF, Neumann R, Rucklinger E, et al. (2004) Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10: 1618-1624.
18. Liu JM, Hankinson SE, Stampfer MJ, Rifai N, Willett WC, et al. (2003) Body iron stores and their determinants in healthy postmenopausal US women. Am J Clin Nutr 78: 1160-1167.
19. O'Meara A, Infanti L, Stebler C, Ruesch M, Sigle JP, et al. (2011) The value of routine ferritin measurement in blood donors. Transfusion 51: 2183-2188.
20. Heikkila K, Ebrahim S, Lawlor DA, (2007) A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 61: 824-833.
21. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, et al. (2008) Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 358: 221-230.
22. Jehn M, Clark JM, Guallar E, (2004) Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 27: 2422-2428.
23. Crawford DC, Sanders CL, Qin X, Smith JD, Shephard C, et al. (2006) Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation 114: 2458-2465.
24. Ma Y, Griffith JA, Chasan-Taber L, Olendzki BC, Jackson E, et al. (2006) Association between dietary fiber and serum C-reactive protein. Am J Clin Nutr 83: 760-766.
25. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET, (2002) Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 105: 564-569.
26. Zhang D, Jiang SL, Rzewnicki D, Samols D, Kushner I, (1995) The effect of interleukin-1 on C-reactive protein expression in Hep3B cells is exerted at the transcriptional level. Biochem J 310 (Pt 1) (): 143-148.
27. Streetz KL, Wustefeld T, Klein C, Manns MP, Trautwein C, (2001) Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-le-grand) 47: 661-673.
28. Tran TN, Eubanks SK, Schaffer KJ, Zhou CY, Linder MC, (1997) Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 90: 4979-4986.
29. Ghosh S, Hevi S, Chuck SL, (2004) Regulated secretion of glycosylated human ferritin from hepatocytes. Blood 103: 2369-2376.
30. Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang DL, et al. (2010) Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 116: 1574-1584.
31. Ferring-Appel D, Hentze MW, Galy B, (2009) Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood 113: 679-687.
32. Zhang Z, Zhang F, An P, Guo X, Shen Y, et al. (2011) Ferroportin1 deficiency in mouse macrophages impairs iron homeostasis and inflammatory responses. Blood 118: 1912-1922.
33. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, et al. (2011) HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19: 31-44.
34. Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, et al. (2011) An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res 71: 6728-6737.
35. Coffman LG, Parsonage D, D'Agostino R Jr, Torti FM, Torti SV, (2009) Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A 106: 570-575.
36. Broxmeyer HE, Williams DE, Geissler K, Hangoc G, Cooper S, et al. (1989) Suppressive effects in vivo of purified recombinant human H-subunit (acidic) ferritin on murine myelopoiesis. Blood 73: 74-79.
37. Todorich B, Zhang X, Connor JR, (2011) H-ferritin is the major source of iron for oligodendrocytes. Glia 59: 927-935.